Literature DB >> 20964249

Temporal bone osteoradionecrosis after surgery and radiotherapy for malignant parotid tumors.

John P Leonetti1, Sam J Marzo, Chad A Zender, Ryan G Porter, Edward Melian.   

Abstract

OBJECTIVE: To assess the incidence of osteoradionecrosis (ORN) of the temporal bone after surgery with radiotherapy for malignant parotid tumors.
SETTING: A tertiary care, academic medical center. PATIENTS: All patients who underwent surgical resection with postoperative radiotherapy (RT) for a malignant parotid tumor between July 1988 and July 2007.
INTERVENTIONS: A retrospective chart analysis to determine the extent of surgery, the RT parameters, and the incidence of ORN of the temporal bone. MAIN OUTCOME MEASURES: The incidence of ORN in 3 subgroups of patients.
RESULTS: The 221 patients with malignant parotid tumors who underwent surgical resection with postoperative RT were divided into groups 1, parotidectomy only; 2, parotidectomy with mastoidectomy; and 3, parotidectomy with subtotal petrosectomy. The overall incidence of temporal bone ORN in group 1 was 2 (2%) of 106; in group 2, 8 (13%) of 64; and in group 3, 0 (0%) of 51.
CONCLUSION: The incidence of temporal bone ORN is higher after mastoidectomy for facial nerve identification or resection in patients undergoing parotidectomy with postoperative radiotherapy. Oversew of the ear canal with mastoid obliteration should be considered in this subgroup of patients to avoid this long-term complication of radiotherapy used in the treatment of malignant parotid tumors.

Entities:  

Mesh:

Year:  2010        PMID: 20964249

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  9 in total

1.  Diffuse osteoradionecrosis of temporal bone as a late complication of adjuvant radiotherapy to parotid bed: a case report.

Authors:  Sisha Liz Abraham; Sivaraman Ganesan; Elizabeth Mathew Iype; Vijay Jagan
Journal:  J Clin Diagn Res       Date:  2014-05-15

2.  Osteoradionecrosis of the mandible and mastoiditis after radiotherapy for parotid mucoepidermoid carcinoma.

Authors:  Kumuda Arvind Rao; Shishir Ram Shetty; Subhas G Babu; Renita Lorina Castelino
Journal:  Clin Med Res       Date:  2011-10-26

3.  Osteoradionecrosis of the Temporal Bone as a Rare Cause of Facial Nerve Palsy.

Authors:  Florian Schmidt; Katy Bradley; Gerd Fabian Volk
Journal:  Diagnostics (Basel)       Date:  2022-04-19

4.  Osteoradionecrosis of the temporal bone: a case series.

Authors:  Jeffrey D Sharon; Shariq S Khwaja; Andrew Drescher; Hiram Gay; Richard A Chole
Journal:  Otol Neurotol       Date:  2014-08       Impact factor: 2.311

5.  CT findings in temporal bone osteoradionecrosis.

Authors:  Salmaan Ahmed; Nakul Gupta; Jackson D Hamilton; Adam S Garden; Paul W Gidley; Lawrence E Ginsberg
Journal:  J Comput Assist Tomogr       Date:  2014 Sep-Oct       Impact factor: 1.826

6.  Cochlear Implant Outcomes: A Comparison between Irradiated and Non-irradiated Ears.

Authors:  Jie Min Soh; Vishal Deepak D'Souza; Gopal Krishna Sarepaka; Win Nie Ng; Chun Suan Ong; Wong Kein Low
Journal:  Clin Exp Otorhinolaryngol       Date:  2012-04-30       Impact factor: 3.372

7.  Cancer of the External Auditory Canal with Extensive Osteoradionecrosis of the Skull Base after Re-Irradiation with Particle Beams: A Case Report.

Authors:  Mioko Matsuo; Ryuji Yasumatsu; Sei Yoshida; Rina Jiroumaru; Kazuki Hashimoto; Takahiro Wakasaki; Takashi Nakagawa
Journal:  Case Rep Oncol       Date:  2021-07-13

8.  Temporal Bone Osteoradionecrosis: An 18-year, Single-Institution Experience.

Authors:  Benjamin D Lovin; Mike Hernandez; Hunter Elms; Jonathan S Choi; Nathan R Lindquist; Amy C Moreno; Marc-Elie Nader; Paul W Gidley
Journal:  Laryngoscope       Date:  2021-07-20       Impact factor: 2.970

9.  Risk profile for osteoradionecrosis of the mandible in the IMRT era.

Authors:  Gabriela Studer; Marius Bredell; Stephan Studer; Gerhard Huber; Christoph Glanzmann
Journal:  Strahlenther Onkol       Date:  2015-08-12       Impact factor: 3.621

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.